Should Physicians Recommend Replacing Opioids With Cannabis?[JAMA. 2019]

Humphreys K, Saitz R

JAMA. 2019 Feb 19; 321(7):639-640.
Loose regulation of medical marijuana programs associated with higher rates of adult marijuana use but not cannabis use disorder.[Addiction. 2017]

Williams AR, Santaella-Tenorio J, Mauro CM, Levin FR, Martins SS

Addiction. 2017 Nov; 112(11):1985-1991.
Review Effects of Cannabis Use on Human Behavior, Including Cognition, Motivation, and Psychosis: A Review.[JAMA Psychiatry. 2016]

Volkow ND, Swanson JM, Evins AE, DeLisi LE, Meier MH, Gonzalez R, Bloomfield MA, Curran HV, Baler R

JAMA Psychiatry. 2016 Mar; 73(3):292-7.

Shattuck Lecture. A molecular basis for nicotine as a gateway drug.[N Engl J Med. 2014]

Kandel ER, Kandel DB

N Engl J Med. 2014 Sep 4; 371(10):932-43.

Review American Academy of Pediatrics. Committee on Substance Abuse. Marijuana: A continuing concern for pediatricians.[Pediatrics. 1999]

Heyman RB, Anglin TM, Copperman SM, Joffe A, McDonald CA, Rogers PD, Shah RZ, Armentano M, Boyd GM, Czechowicz D

Pediatrics. 1999 Oct; 104(4 Pt 1):982-5.

The economic burden of the opioid epidemic on states: the case of Medicaid.[Am J Manag Care. 2019]

Leslie DL, Ba DM, Agbese E, Xing X, Liu G

Am J Manag Care. 2019 Jul; 25(13 Suppl):S243-S249.

Review Neural mechanisms of drug reinforcement.[Ann N Y Acad Sci. 1992]

Koob GF

Ann N Y Acad Sci. 1992 Jun 28; 654():171-91.
Review Dopamine and reward: the anhedonia hypothesis 30 years on.[Neurotox Res. 2008]

Wise RA

Neurotox Res. 2008 Oct; 14(2-3):169-83.
Review Neurobiologic Advances from the Brain Disease Model of Addiction.[N Engl J Med. 2016]

Volkow ND, Koob GF, McLellan AT

N Engl J Med. 2016 Jan 28; 374(4):363-71.
Assessing and improving clinical insight among patients "in denial".[JAMA Psychiatry. 2015]

Williams AR, Olfson M, Galanter M

JAMA Psychiatry. 2015 Apr; 72(4):303-4.

Promising treatments for women with comorbid PTSD and substance use disorders.[Am J Psychiatry. 2004]

Hien DA, Cohen LR, Miele GM, Litt LC, Capstick C

Am J Psychiatry. 2004 Aug; 161(8):1426-32.
Childhood abuse, neglect, and household dysfunction and the risk of illicit drug use: the adverse childhood experiences study.[Pediatrics. 2003]

Dube SR, Felitti VJ, Dong M, Chapman DP, Giles WH, Anda RF

Pediatrics. 2003 Mar; 111(3):564-72.

Review Lower-Risk Cannabis Use Guidelines: A Comprehensive Update of Evidence and Recommendations.[Am J Public Health. 2017]

Fischer B, Russell C, Sabioni P, van den Brink W, Le Foll B, Hall W, Rehm J, Room R

Am J Public Health. 2017 Aug; 107(8):e1-e12.

Grey Matter Volume Differences Associated with Extremely Low Levels of Cannabis Use in Adolescence.[J Neurosci. 2019]

Orr C, Spechler P, Cao Z, Albaugh M, Chaarani B, Mackey S, D'Souza D, Allgaier N, Banaschewski T, Bokde ALW, Bromberg U, Büchel C, Burke Quinlan E, Conrod P, Desrivières S, Flor H, Frouin V, Gowland P, Heinz A, Ittermann B, Martinot JL, Martinot MP, Nees F, Papadopoulos Orfanos D, Paus T, Poustka L, Millenet S, Fröhner JH, Radhakrishnan R, Smolka MN, Walter H, Whelan R, Schumann G, Potter A, Garavan H

J Neurosci. 2019 Mar 6; 39(10):1817-1827.

Endocannabinoid-Enhanced "Liking" in Nucleus Accumbens Shell Hedonic Hotspot Requires Endogenous Opioid Signals.[Cannabis Cannabinoid Res. 2018]

Mitchell MR, Berridge KC, Mahler SV

Cannabis Cannabinoid Res. 2018; 3(1):166-170.

Strain dependence of adolescent Cannabis influence on heroin reward and mesolimbic dopamine transmission in adult Lewis and Fischer 344 rats.[Addict Biol. 2015]

Cadoni C, Simola N, Espa E, Fenu S, Di Chiara G

Addict Biol. 2015 Jan; 20(1):132-42.
Trajectory of adolescent cannabis use on addiction vulnerability.[Neuropharmacology. 2014]

Hurd YL, Michaelides M, Miller ML, Jutras-Aswad D

Neuropharmacology. 2014 Jan; 76 Pt B():416-24.

Impact of co-administration of oxycodone and smoked cannabis on analgesia and abuse liability.[Neuropsychopharmacology. 2018]

Cooper ZD, Bedi G, Ramesh D, Balter R, Comer SD, Haney M

Neuropsychopharmacology. 2018 Sep; 43(10):2046-2055.
States Move to Substitute Opioids With Medical Marijuana to Quell Epidemic.[JAMA. 2018]

Voelker R

JAMA. 2018 Dec 18; 320(23):2408-2410.
Cannabis and the Current State of Treatment for Cannabis Use Disorder.[Focus (Am Psychiatr Publ). 2019]

Williams AR, Hill KP

Focus (Am Psychiatr Publ). 2019 Apr; 17(2):98-103.

Cannabis Use and Risk of Prescription Opioid Use Disorder in the United States.[Am J Psychiatry. 2018]

Olfson M, Wall MM, Liu SM, Blanco C

Am J Psychiatry. 2018 Jan 1; 175(1):47-53.
Medical Marijuana Users are More Likely to Use Prescription Drugs Medically and Nonmedically.[J Addict Med. 2018]

Caputi TL, Humphreys K

J Addict Med. 2018 Jul/Aug; 12(4):295-299.
Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010.[JAMA Intern Med. 2014]

Bachhuber MA, Saloner B, Cunningham CO, Barry CL

JAMA Intern Med. 2014 Oct; 174(10):1668-73.
Association between medical cannabis laws and opioid overdose mortality has reversed over time.[Proc Natl Acad Sci U S A. 2019]

Shover CL, Davis CS, Gordon SC, Humphreys K

Proc Natl Acad Sci U S A. 2019 Jun 25; 116(26):12624-12626.

Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study.[Lancet Psychiatry. 2015]

Di Forti M, Marconi A, Carra E, Fraietta S, Trotta A, Bonomo M, Bianconi F, Gardner-Sood P, O'Connor J, Russo M, Stilo SA, Marques TR, Mondelli V, Dazzan P, Pariante C, David AS, Gaughran F, Atakan Z, Iyegbe C, Powell J, Morgan C, Lynskey M, Murray RM

Lancet Psychiatry. 2015 Mar; 2(3):233-8.
Association of Prenatal Cannabis Exposure With Psychosis Proneness Among Children in the Adolescent Brain Cognitive Development (ABCD) Study.[JAMA Psychiatry. 2019]

Fine JD, Moreau AL, Karcher NR, Agrawal A, Rogers CE, Barch DM, Bogdan R

JAMA Psychiatry. 2019 Jul 1; 76(7):762-764.